Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.

BACKGROUND

Asciminib is approved for treating patients with chronic-phase chronic myeloid leukemia who were previously treated with two or more tyrosine kinase inhibitors or those with mutation. However, the mechanisms underlying asciminib resistance remain unclear.

METHODS

In this study, we established a new asciminib-resistant cell line. We examined gene mutation analysis and the effects of conventional chronic myelogenous leukemia inhibitors.

RESULTS

Direct sequencing revealed and mutations in asciminib-resistant cells. Ponatinib and omacetaxine were effective against asciminib-resistant cells.

CONCLUSIONS

and mutations are extremely resistant to asciminib. Ponatinib and omacetaxine show potential for treating asciminib-resistant chronic myeloid leukemia.